BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. Gut. 2003;52:1784-1787. [PMID: 14633963 DOI: 10.1136/gut.52.12.1784] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Nguyen-khac E, Capron D, Castelain S, François C, Braillon A. Personalized therapy for chronic viral hepatitis C in the naive patient: How can we optimize treatment duration as a function of viral genotype? European Journal of Internal Medicine 2007;18:510-5. [DOI: 10.1016/j.ejim.2007.02.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
2 Pol S, Marcellin P. Prise en charge de l’hépatite C en 2008. Gastroentérologie Clinique et Biologique 2008;32:S71-3. [DOI: 10.1016/s0399-8320(08)73268-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, Giuily N, Castelnau C, Cardoso AC, Asselah T. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008;135:821-829. [PMID: 18593587 DOI: 10.1053/j.gastro.2008.05.044] [Cited by in Crossref: 227] [Cited by in F6Publishing: 198] [Article Influence: 16.2] [Reference Citation Analysis]
4 François C, Descamps V, Brochot E, Bernard I, Canva V, Mathurin P, Castelain S, Duverlie G. Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy. J Med Virol 2010;82:1640-6. [PMID: 20827759 DOI: 10.1002/jmv.21837] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
5 Knight R, Roux P, Vilotitch A, Marcellin F, Rosenthal E, Esterle L, Boué F, Rey D, Piroth L, Dominguez S, Sogni P, Salmon-Ceron D, Spire B, Carrieri MP; ANRS CO13-HEPAVIH Study Group. Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort. Addiction 2017;112:1669-79. [PMID: 28430385 DOI: 10.1111/add.13851] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
6 Zeuzem S, Alberti A, Rosenberg W, Marcellin P, Diago M, Negro F, Prati D, Puoti C, Roberts SK, Shiffman ML. Review article: management of patients with chronic hepatitis C virus infection and 'normal' alanine aminotransferase activity. Aliment Pharmacol Ther 2006;24:1133-49. [DOI: 10.1111/j.1365-2036.2006.03073.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
7 Couzigou P, Mathurin P, Serfaty L, Cacoub P, Moussalli J, Pialoux G, Chossegros P, Cattan L, Pol S. [Alcohol, steatohepatitis, insulin resistance and hepatitis C]. Gastroenterol Clin Biol 2008;32:S74-81. [PMID: 18675184 DOI: 10.1016/S0399-8320(08)73269-X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Mihm U, Herrmann E, Sarrazin C, Zeuzem S. Review article: predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 2006;23:1043-54. [DOI: 10.1111/j.1365-2036.2006.02863.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
9 Martinot-peignoux M, Comanor L, Minor JM, Ripault MP, Pham B, Boyer N, Castelnau C, Giuily N, Hendricks D, Marcellin P. Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C. J Viral Hepat 2006;13:701-7. [DOI: 10.1111/j.1365-2893.2006.00750.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
10 Marcellin F, Lions C, Rosenthal E, Roux P, Sogni P, Wittkop L, Protopopescu C, Spire B, Salmon-Ceron D, Dabis F, Carrieri MP; HEPAVIH ANRS CO13 Study Group*. No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort). Drug Alcohol Rev 2017;36:227-38. [PMID: 27073179 DOI: 10.1111/dar.12398] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
11 Seme K, Močilnik T, Poljak M. Twenty-four mini-pool HCV RNA screening in a routine clinical virology laboratory setting: A six-year prospective study. Journal of Virological Methods 2011;171:303-5. [DOI: 10.1016/j.jviromet.2010.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Marcellin P. L’hépatite C en 2007 « Des progrès. Peut-on mieux faire… ». Gastroentérologie Clinique et Biologique 2007;31:3-6. [DOI: 10.1016/s0399-8320(07)92556-7] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
13 Chen W, Li XM, Li AL, Yang G, Hu HN. Hepatitis C Virus Increases Free Fatty Acids Absorption and Promotes its Replication Via Down-Regulating GADD45α Expression. Med Sci Monit 2016;22:2347-56. [PMID: 27381636 DOI: 10.12659/msm.899591] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Carvalho-Filho RJ, Dalgard O. Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin. Pharmgenomics Pers Med 2010;3:1-13. [PMID: 23226039 DOI: 10.2147/pgpm.s4461] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Carrieri MP, Lions C, Sogni P, Winnock M, Roux P, Mora M, Bonnard P, Salmon D, Dabis F, Spire B. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study. J Hepatol. 2014;60:46-53. [PMID: 23978720 DOI: 10.1016/j.jhep.2013.08.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
16 Christensen PB, Krarup HB, Møller A, Laursen AL, Kjaer MS, Orholm M, Lindberg J, Groenbaek K, Kromann-Andersen H, Weis N; Danhep Group. Liver biopsy performance and histological findings among patients with chronic viral hepatitis: a Danish database study. Scand J Infect Dis 2007;39:245-9. [PMID: 17366055 DOI: 10.1080/00365540600978864] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
17 Overbeck K, Bruggmann P, Helbling B. Chronic Hepatitis C virus infection in Swiss primary care practices: Low case loads—high barriers to treatment? European Journal of General Practice 2011;17:103-8. [DOI: 10.3109/13814788.2010.545122] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
18 Márquez-Peiró JF, Pérez-Peiró C, Carmena-Carmena J, Jiménez-Torres NV. [Identifying improvement opportunities in the management of hepatitis C]. Farm Hosp 2006;30:154-60. [PMID: 16999562 DOI: 10.1016/s1130-6343(06)73966-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Defossez G, Verneau A, Ingrand I, Silvain C, Ingrand P, Beauchant M; Poitou-Charentes Hepatitis C Network. Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: a comparative cross-sectional study in Poitou-Charentes region. Eur J Gastroenterol Hepatol 2008;20:367-72. [PMID: 18403936 DOI: 10.1097/MEG.0b013e3282f479ab] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
20 Marcellin F, Lions C, Winnock M, Salmon D, Durant J, Spire B, Mora M, Loko MA, Dabis F, Dominguez S. Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort). Addiction. 2013;108:1250-1258. [PMID: 23421419 DOI: 10.1111/add.12149] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
21 Bailey J. An assessment of the use of chimpanzees in hepatitis C research past, present and future: 1. Validity of the chimpanzee model. Altern Lab Anim 2010;38:387-418. [PMID: 21105756 DOI: 10.1177/026119291003800501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
22 Márquez-Peiró JF, Valero-Alcocer VE, Morales-Suárez-Varela MM, Llopis-González A, Pérez-Peiró C. [Effectiveness of peginterferon alpha-2a or -2b plus ribavirin in naïve patients with hepatitis C infection]. Enferm Infecc Microbiol Clin 2008;26:135-40. [PMID: 18358211 DOI: 10.1157/13116749] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Payan C, Pivert A, Morand P, Fafi-Kremer S, Carrat F, Pol S, Cacoub P, Perronne C, Lunel F; ANRS HC02 RIBAVIC study team. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients. Gut 2007;56:1111-6. [PMID: 17363475 DOI: 10.1136/gut.2006.106690] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
24 Daw MA, Dau AA, Agnan MM. Influence of healthcare-associated factors on the efficacy of hepatitis C therapy. ScientificWorldJournal. 2012;2012:580216. [PMID: 23346018 DOI: 10.1100/2012/580216] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
25 Marcellin P, Grotzinger K, Theodore D, Demuth D, Manns M, Bañares Cañizares R, Pike J, Forssen UM. Severity of liver disease among chronic hepatitis C patients: an observational study of 4594 patients in five European countries. J Gastroenterol Hepatol 2015;30:364-71. [PMID: 25088088 DOI: 10.1111/jgh.12698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
26 Seme K, Močilnik T, Fujs K, Babič DZ, Todorović A, Fras-stefan T, Poljak M. Twenty-four mini-pool HCV RNA screening outside a blood transfusion setting: Results of a 2-year prospective study. Journal of Virological Methods 2007;140:218-21. [DOI: 10.1016/j.jviromet.2006.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
27 Loko MA, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, Gillet S, Pambrun E, Delaune J, Valantin MA. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis. 2010;10:303. [PMID: 20969743 DOI: 10.1186/1471-2334-10-303] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 5.7] [Reference Citation Analysis]
28 Costentin CE, Trabut JB, Mallet V, Darbeda S, Thépot V, Nalpas B, Badin de Montjoye B, Lavielle B, Vallet-Pichard A, Sogni P, Pol S. Management of hepatitis C virus infection in heavy drinkers. Alcohol Alcohol 2013;48:337-42. [PMID: 23518789 DOI: 10.1093/alcalc/agt020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
29 François C, Castelain S, Duverlie G, Capron D, Nguyen-Khac E. Optimizing the treatment of chronic viral hepatitis C. Expert Rev Gastroenterol Hepatol 2009;3:607-13. [PMID: 19929582 DOI: 10.1586/egh.09.60] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
30 Márquez Peiró JF, Valero Alcocer VE, Morales Suárez-Varela M, Llopis González A, Pérez Peiró C. [Toxicity of the treatment of chronic hepatitis C with peginterferon alpha (2a or 2b) plus ribavirin in patients not previously treated]. Med Clin (Barc) 2007;129:612-4. [PMID: 18001672 DOI: 10.1157/13111808] [Reference Citation Analysis]
31 Farnik H, Mihm U, Zeuzem S. Optimal therapy in genotype 1 patients. Liver Int 2009;29 Suppl 1:23-30. [PMID: 19207963 DOI: 10.1111/j.1478-3231.2008.01969.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
32 Posthouwer D, Mauser-Bunschoten EP, Fischer K, VAN Erpecum KJ, DE Knegt RJ. Significant liver damage in patients with bleeding disorders and chronic hepatitis C: non-invasive assessment of liver fibrosis using transient elastography. J Thromb Haemost. 2007;5:25-30. [PMID: 17239163 DOI: 10.1111/j.1538-7836.2006.02272.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
33 Broers B, Helbling B, François A, Schmid P, Chuard C, Hadengue A, Negro F; Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005;42:323-8. [PMID: 15791696 DOI: 10.1016/j.jhep.2004.11.018] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 3.8] [Reference Citation Analysis]
34 Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int 2009;29 Suppl 1:1-8. [PMID: 19207959 DOI: 10.1111/j.1478-3231.2008.01947.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 5.8] [Reference Citation Analysis]
35 Cadranel JF, Nousbaum JB. [Current trends in liver biopsy indications in chronic liver diseases]. Presse Med 2012;41:1064-70. [PMID: 22425478 DOI: 10.1016/j.lpm.2012.01.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
36 Hermetet C, Dubois F, Gaudy-Graffin C, Bacq Y, Royer B, Gaborit C, D'Alteroche L, Desenclos JC, Roingeard P, Grammatico-Guillon L. Continuum of hepatitis C care in France: A 20-year cohort study. PLoS One 2017;12:e0183232. [PMID: 28850623 DOI: 10.1371/journal.pone.0183232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
37 Lambert J, Halfon P, Penaranda G, Bedossa P, Cacoub P, Carrat F. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem 2008;54:1372-8. [PMID: 18539647 DOI: 10.1373/clinchem.2007.097923] [Cited by in Crossref: 97] [Cited by in F6Publishing: 93] [Article Influence: 6.9] [Reference Citation Analysis]
38 Sanai FM, Benmousa A, Al-hussaini H, Ashraf S, Alhafi O, Abdo AA, Alameri HF, Akbar HO, Bzeizi KI. Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C infection?: Hepatitis C virus and liver histology. Liver International 2008;28:1011-8. [DOI: 10.1111/j.1478-3231.2008.01733.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
39 Hui CK, Zhang HY, Shek T, Yao H, Yueng YH, Leung KW, Lai ST, Lai JY, Leung N, Lau GK. Disease progression in Chinese chronic hepatitis C patients with persistently normal alanine aminotransaminase levels. Aliment Pharmacol Ther 2007;25:1283-92. [PMID: 17509096 DOI: 10.1111/j.1365-2036.2007.03318.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
40 Bochud P, Cai T, Overbeck K, Bochud M, Dufour J, Müllhaupt B, Borovicka J, Heim M, Moradpour D, Cerny A, Malinverni R, Francioli P, Negro F. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. Journal of Hepatology 2009;51:655-66. [DOI: 10.1016/j.jhep.2009.05.016] [Cited by in Crossref: 191] [Cited by in F6Publishing: 173] [Article Influence: 14.7] [Reference Citation Analysis]
41 Lisker-melman M, Sayuk GS. Defining Optimal Therapeutic Outcomes in Chronic Hepatitis. Archives of Medical Research 2007;38:652-60. [DOI: 10.1016/j.arcmed.2006.10.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
42 Marcellin P. [Hepatitis C: the recovery]. Gastroenterol Clin Biol 2009;33:819-29. [PMID: 19541439 DOI: 10.1016/j.gcb.2009.05.002] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
43 Cadranel JD, Nousbaum J, Gouillou M, Hanslik B. Major changes in the number and indications of liver biopsy for chronic liver diseases over one decade in France: . European Journal of Gastroenterology & Hepatology 2016;28:e26-32. [DOI: 10.1097/meg.0000000000000683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
44 Asselah T, Marcellin P. BILN 2061: a major step toward new therapeutic strategies in hepatitis C. Journal of Hepatology 2004;41:178-81. [DOI: 10.1016/j.jhep.2004.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
45 Serres L, Vasseur P, Tougeron D, Gand E, Chagneau-Derrode C, Charier F, Rochd S, Silvain C. Cardiovascular events in chronic hepatitis C: prognostic value of liver stiffness evolution. Eur J Gastroenterol Hepatol 2015;27:1286-92. [PMID: 26275081 DOI: 10.1097/MEG.0000000000000453] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
46 Zittoon RF, Madian YT, Alhennawi DEM, Nadeem HS. Cochlear Changes Caused by Peginterferon α-2b. J Interferon Cytokine Res 2018;38:311-6. [PMID: 30016180 DOI: 10.1089/jir.2018.0012] [Reference Citation Analysis]
47 Delarocque-Astagneau E, Meffre C, Dubois F, Pioche C, Le Strat Y, Roudot-Thoraval F, Hillon P, Silvain C, Dhumeaux D, Desenclos JC. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat. 2010;17:435-443. [PMID: 19780936 DOI: 10.1111/j.1365-2893.2009.01196.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
48 Morin T, Pariente A, Lahmek P, Rabaud C, Silvain C, Cadranel JF; Association Nationale des Hépato-gastroentérologues des Hôpitaux généraux (ANGH) Société de Pathologie Infectieuse de Langue Française (SPILF) Fédération des Pôles de Référence et Réseaux Hépatites (FPRRH). Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Eur J Gastroenterol Hepatol 2010;22:157-66. [PMID: 19734798 DOI: 10.1097/MEG.0b013e328330a8e8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
49 Larsen C, Bousquet V, Delarocque-Astagneau E, Pioche C, Roudot-Thoraval F; HCV Surveillance Steering Committee; HCV Surveillance Group, Desenclos JC. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France. J Med Virol. 2010;82:1647-1654. [PMID: 20827760 DOI: 10.1002/jmv.21850] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
50 Halfon P, Bourliere M, Deydier R, Botta-fridlund D, Renou C, Tran A, Portal I, Allemand I, Bertrand JJ, Rosenthal-allieri A, Rotily M, Sattonet C, Benderitter T, Paul MCS, Bonnot HP, Penaranda G, Degott C, Masseyeff MF, Ouzan D. Independent Prospective Multicenter Validation of Biochemical Markers (Fibrotest-Actitest) for the Prediction of Liver Fibrosis and Activity in Patients with Chronic Hepatitis C: The Fibropaca Study. Am J Gastroenterology 2006;101:547-55. [DOI: 10.1111/j.1572-0241.2006.00411.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 99] [Article Influence: 6.1] [Reference Citation Analysis]
51 Elloumi H, Houissa F, Hadj NB, Gargouri D, Romani M, Kharrat J, Ghorbel A. Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment. World J Gastroenterol 2007; 13(40): 5411-5412 [PMID: 17879419 DOI: 10.3748/wjg.v13.i40.5411] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
52 Jensen DM, Marcellin P. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. Eur J Gastroenterol Hepatol 2005;17:899-904. [PMID: 16093865 DOI: 10.1097/00042737-200509000-00003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
53 Diago M. [Treatment of hepatitis C virus infection: current status and perspectives]. Gastroenterol Hepatol 2008;31:596-605. [PMID: 19091249 DOI: 10.1157/13128300] [Reference Citation Analysis]